Transferred WT1-Reactive CD8+ T Cells Can Mediate Antileukemic Activity and Persist in Post-Transplant Patients | Science Translational Medicine

Skip to main content

ScienceMag.org

Read our COVID-19 research and news.

Article Information

vol. 5 no. 174 174ra27

DOI:

https://doi.org/10.1126/scitranslmed.3004916

PubMed:

Published By:

American Association for the Advancement of Science

Print ISSN:

Online ISSN:

History:

Received for publication September 6, 2012
Accepted for publication January 31, 2013
.

Copyright & Usage:

Copyright © 2013, American Association for the Advancement of Science

Author Information

Aude G. Chapuis¹,*,
Gunnar B. Ragnarsson¹,*,†,
Hieu N. Nguyen¹,
Colette N. Chaney¹,
Jeffrey S. Pufnock¹,‡,
Thomas M. Schmitt¹,
Natalie Duerkopp¹,
Ilana M. Roberts¹,§,
Galina L. Pogosov²,
William Y. Ho¹,¶,
Sebastian Ochsenreither¹,||,
Matthias Wölfl¹,**,
Merav Bar²,
Jerald P. Radich²,
Cassian Yee¹,††‡‡ and
Philip D. Greenberg¹,³,‡‡

¹Program in Immunology, Fred Hutchinson Cancer Research Center (FHCRC), Seattle, WA 98109, USA.
²Clinical Research Division, FHCRC, Seattle, WA 98109, USA.
³Department of Immunology, University of Washington, Seattle, WA 98195, USA.

↵‡‡To whom correspondence should be addressed. E-mail: pgreen{at}u.washington.edu (P.D.G.); cyee{at}fhcrc.org (C.Y.)

↵* These authors contributed equally to this work.
↵† Present address: Landspítali Háskólasjúkrahús, 101 Reykjavík, Iceland.
↵‡ Present address: Seattle Children’s Research Institute, Seattle, WA 98101, USA.
↵§ Present address: Surgery Branch, National Institutes of Health, Bethesda, MD 20892, USA.
↵¶ Present address: Igenica Inc., Burlingame, CA 94010, USA.
↵|| Present address: Department of Hematology, Charité, 10117 Berlin, Germany.
↵** Present address: University Children’s Hospital, 97070 Würzburg, Germany.
↵†† Present address: Department of Immunology, MD Anderson Cancer Center, Houston, TX 77030, USA.

Altmetric

Article usage

Article usage: February 2013 to March 2021

	Abstract	Full	Pdf
Feb 2013	1661	57	144
Mar 2013	3632	119	382
Apr 2013	693	25	76
May 2013	524	22	71
Jun 2013	443	27	77
Jul 2013	283	8	42
Aug 2013	191	13	34
Sep 2013	198	20	29
Oct 2013	224	14	25
Nov 2013	173	10	16
Dec 2013	191	6	19
Jan 2014	234	18	44
Feb 2014	242	35	43
Mar 2014	147	42	30
Apr 2014	158	41	34
May 2014	143	48	41
Jun 2014	212	26	30
Jul 2014	183	33	25
Aug 2014	194	32	33
Sep 2014	236	28	30
Oct 2014	598	30	21
Nov 2014	262	19	22
Dec 2014	89	28	30
Jan 2015	217	63	44
Feb 2015	96	25	22
Mar 2015	201	46	45
Apr 2015	98	32	20
May 2015	107	19	25
Jun 2015	113	12	11
Jul 2015	104	9	25
Aug 2015	40	6	18
Sep 2015	23	24	60
Oct 2015	6	10	41
Nov 2015	27	13	55
Dec 2015	37	10	51
Jan 2016	98	7	40
Feb 2016	92	9	43
Mar 2016	116	16	52
Apr 2016	116	18	51
May 2016	160	24	32
Jun 2016	148	17	30
Jul 2016	121	7	22
Aug 2016	116	15	28
Sep 2016	93	3	10
Oct 2016	131	10	22
Nov 2016	142	21	30
Dec 2016	89	7	11
Jan 2017	87	11	16
Feb 2017	106	13	14
Mar 2017	159	6	19
Apr 2017	109	12	13
May 2017	108	5	13
Jun 2017	71	6	12
Jul 2017	94	7	12
Aug 2017	112	14	15
Sep 2017	129	6	6
Oct 2017	115	15	18
Nov 2017	86	6	15
Dec 2017	84	3	7
Jan 2018	89	3	12
Feb 2018	97	9	15
Mar 2018	84	11	7
Apr 2018	160	10	10
May 2018	132	6	11
Jun 2018	104	6	12
Jul 2018	76	15	11
Aug 2018	58	24	18
Sep 2018	75	18	10
Oct 2018	95	14	14
Nov 2018	107	15	10
Dec 2018	103	22	4
Jan 2019	87	21	18
Feb 2019	66	21	13
Mar 2019	74	29	17
Apr 2019	42	19	10
May 2019	50	29	8
Jun 2019	29	15	6
Jul 2019	65	37	36
Aug 2019	58	25	12
Sep 2019	32	35	17
Oct 2019	43	34	12
Nov 2019	31	18	10
Dec 2019	53	19	8
Jan 2020	45	18	4
Feb 2020	47	16	14
Mar 2020	48	27	11
Apr 2020	38	16	9
May 2020	43	16	9
Jun 2020	49	12	5
Jul 2020	22	8	4
Aug 2020	33	12	12
Sep 2020	28	14	5
Oct 2020	42	17	7
Nov 2020	34	11	9
Dec 2020	43	19	12
Jan 2021	40	8	6
Feb 2021	30	20	14
Mar 2021	6	2	1

Science Translational Medicine: 5 (174)

Science Translational Medicine

Vol 5, Issue 174
27 February 2013

Table of Contents

Article Tools

Email

Thank you for your interest in spreading the word about Science Translational Medicine.
NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Your Email

Your Name

Send To
Enter multiple addresses on separate lines or separate them with commas.

You are going to email the following Transferred WT1-Reactive CD8+ T Cells Can Mediate Antileukemic Activity and Persist in Post-Transplant Patients

Message Subject (Your Name) has forwarded a page to you from Science Translational Medicine

Message Body (Your Name) thought you would like to see this page from the Science Translational Medicine web site.

Your Personal Message

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Download Powerpoint
Print
Alerts

Please log in to add an alert for this article.

Log In with your AAAS ID

Sign In to Email Alerts with your Email Address
Email
Citation tools
Transferred WT1-Reactive CD8⁺ T Cells Can Mediate Antileukemic Activity and Persist in Post-Transplant Patients

By Aude G. Chapuis, Gunnar B. Ragnarsson, Hieu N. Nguyen, Colette N. Chaney, Jeffrey S. Pufnock, Thomas M. Schmitt, Natalie Duerkopp, Ilana M. Roberts, Galina L. Pogosov, William Y. Ho, Sebastian Ochsenreither, Matthias Wölfl, Merav Bar, Jerald P. Radich, Cassian Yee, Philip D. Greenberg

Science Translational Medicine27 Feb 2013 : 174ra27

Donor-derived WT1-specific CD8⁺ T cells transferred after hematopoietic cell transplantation mediate antileukemic activity and can establish persistent responses without toxicity to normal tissues in high-risk leukemia patients.

Citation Manager Formats

BibTeX

Bookends

EasyBib

EndNote (tagged)

EndNote 8 (xml)

Medlars

Mendeley

Papers

RefWorks Tagged

Ref Manager

RIS

Zotero
Share

Transferred WT1-Reactive CD8⁺ T Cells Can Mediate Antileukemic Activity and Persist in Post-Transplant Patients

By Aude G. Chapuis, Gunnar B. Ragnarsson, Hieu N. Nguyen, Colette N. Chaney, Jeffrey S. Pufnock, Thomas M. Schmitt, Natalie Duerkopp, Ilana M. Roberts, Galina L. Pogosov, William Y. Ho, Sebastian Ochsenreither, Matthias Wölfl, Merav Bar, Jerald P. Radich, Cassian Yee, Philip D. Greenberg

Science Translational Medicine27 Feb 2013 : 174ra27

Donor-derived WT1-specific CD8⁺ T cells transferred after hematopoietic cell transplantation mediate antileukemic activity and can establish persistent responses without toxicity to normal tissues in high-risk leukemia patients.

Share This Article:

My saved folders

Save to my folders

Log In with your AAAS ID

Stay Connected to Science Translational Medicine

Citing Articles in: